AstraZeneca boosts patent portfolio with lung drug acquisition

UK-based pharmaceutical company AstraZeneca has boosted its patent portfolio with the acquisition of rights to Spanish company Almirall’s lung drugs, including Eklira (aclidinium).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Beyond the primary patent: How pharma can build competitive barriers

16 September 2026 A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.

Pharma

J&J unit win shuts door on Sandoz generic launch

10 September 2026 Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.

Pharma

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

7 September 2026 A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.

More features

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Australian biotech sues Grail over multi-cancer blood test

K&L Gates hires six-partner team of IP and corporate lawyers from Pillsbury

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients

Built to be bought? What makes companies acquisition-ready

Patent lawyers and judges discuss lofty UPC issues in grand London venue

J&J names two-decade veteran as chief IP counsel

AstraZeneca boosts patent portfolio with lung drug acquisition

More on this story

Editor's picks

Editor's picks

More features